Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development

Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies

(2015) V. Bachanova et al.   CLINICAL CANCER RESEARCH

Quercetin 3-O-glucoside suppresses epidermal growth factor–induced migration by inhibiting EGFR signaling in pancreatic cancer cells

(2015) Jungwhoi Lee et al.   TUMOR BIOLOGY

Diphtheria toxin-based targeted toxin therapy for brain tumors

(2013) Yan Michael Li et al.   JOURNAL OF NEURO-ONCOLOGY

A Deimmunized Bispecific Ligand-Directed Toxin That Shows an Impressive Anti–Pancreatic Cancer Effect in a Systemic Nude Mouse Orthotopic Model

(2012) Seunguk Oh et al.   PANCREAS

Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body

(2010) Shunmugaperumal Tamilvanan et al.   JOURNAL OF DRUG TARGETING

A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature

(2010) Alexander K. Tsai et al.   JOURNAL OF NEURO-ONCOLOGY

Bioengineering a Unique Deimmunized Bispecific Targeted Toxin That Simultaneously Recognizes Human CD22 and CD19 Receptors in a Mouse Model of B-Cell Metastases

(2010) D. A. Vallera et al.   MOLECULAR CANCER THERAPEUTICS

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity

(2009) B J Stish et al.   BRITISH JOURNAL OF CANCER

A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast Carcinoma

(2009) S. Oh et al.   CLINICAL CANCER RESEARCH

Anti-CD3 Recombinant Diphtheria Immunotoxin Therapy of Cutaneous T Cell Lymphoma

(2009) A. Frankel et al.   CURRENT DRUG TARGETS

Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies

(2009) Robert Kreitman   CURRENT PHARMACEUTICAL DESIGN

Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy

(2009) Daniel A. Vallera et al.   LEUKEMIA RESEARCH

Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model

(2008) D. A. Vallera et al.   GUT